|
COPYRIGHT 2001 PR Newswire Association LLC
HEIDELBERG, Germany, May 31 /PRNewswire/ --
Graffinity Pharmaceutical Design, today announced a drug discovery alliance with Aventis Pharma. Financial terms were not disclosed.
Under the agreement, Graffinity will use its proprietary chemical micro-array based discovery platform for identification of novel lead structures for Aventis targets.
CEO of Graffinity Dr. Dirk Vetter...
Read the full article for free courtesy of your local library.
| 
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
